Schaeffer's Top Stock Picks for '25

Activision Blizzard, Arista Networks Stocks Pacing for Records After Earnings

Morgan Stanley's new price target is still below BLUE's Thursday close

Nov 3, 2017 at 9:27 AM
facebook X logo linkedin


Analysts are weighing in on video game stock Activision Blizzard, Inc. (NASDAQ:ATVI), cloud concern Arista Networks Inc (NYSE:ANET), and gene therapy specialist bluebird bio Inc (NASDAQ:BLUE). Here's a quick roundup of today's bullish brokerage notes on shares of ATVI, ANET, and BLUE.

Activision Stock Eyes Record Highs on Call of Duty Release Day

Activision Blizzard stock is up 2.4% before the open, after the company reported a third-quarter beat and upwardly revised its full-year outlook. This news comes as the firm's highly anticipated Call of Duty: WWII game begins to hit the shelves today. Meanwhile, Barclays raised its price target to $66 from $65, while Jefferies upped its target to $82 from $80. Most analysts are already very bullish on the shares, with 17 of 21 covering brokerage firms rating the equity a "buy" or "strong buy."

After closing yesterday at $65.45, this morning's pre-market move puts ATVI on pace to open at a record high. Still, the pending price action is well below what options traders were pricing in.

ANET Stock Set for Huge Post-Earnings Session

Arista Networks stock is in line for an even bigger post-earnings rally, with the shares pointed 11% higher before the open. The cloud company blew past Wall Street's third-quarter estimates, resulting in several bullish notes from analysts. For example, D.A. Davidson upgraded ANET to "buy" from "neutral," and raised its price target to $224 from $180.

The security actually pulled back sharply yesterday ahead of the quarterly event, settling at $181.17, but it remains up more than 87% year-to-date, and could take out its Oct. 31 record high of $201.95 today. Many options traders were betting on more gains, too, based on Arista Networks' 10-day call/put volume ratio of 1.47 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which ranks in the 79th annual percentile -- meaning call buying has been unusually popular relative to put buying.

Morgan Stanley Upgrades High-Flying Bluebird Bio

Morgan Stanley this morning upgraded bluebird bio stock to "equal weight" from "underweight," and boosted its price target to $151 from $105. However, this is still below the equity's Thursday close of $154.05. An upbeat earnings report recently sent BLUE shares to a two-year high of $161.82 earlier this week, and they currently sport a 52-week gain of 232%. But even after a 41.5% decline in the last two reporting periods, short interest represents 11.2% of the security's float, suggesting bluebird bio could benefit from a short-squeeze situation.

 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?